Company intelligence / Profile preview

SkinJect

Pittsburgh, Pennsylvania, United Statesskinjectpatch.com ↗

Ownership: Private
Development stage: Preclinical

Overview

SkinJect has completed a Phase 1 trial demonstrating safety and tolerability of its dissolvable doxorubicin microneedle patch in basal cell carcinoma, with some complete responses observed. A randomized, double-blind, placebo-controlled Phase 2 study in nodular basal cell carcinoma is ongoing at multiple US sites; interim data analysis is expected Q1 2025. The technology aims to provide a less invasive alternative to surgery with potential for improved recurrence rates and patient compliance[3][5][7].

Therapeutic areas: Oncology
Modalities: DeviceSmall molecule (doxorubicin)Biologic (by mechanism, as it induces immune response[8])
Industry: Biotech

Partnerships

Academic licensing partnership with University of Pittsburgh Innovation Institute[4].No major pharma partnerships disclosed.Key private equity/institutional investors include RBx Capital LP and Velocity Fund Partners[3].

Beyond the preview

Go deeper on SkinJect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SkinJect.

Explore the full profile